Publications by authors named "A J Zurita"
Article Synopsis
- The research investigates how prostate cancer adapts to changing environments and the role of the Polyaneuploid Cancer Cell (PACC) state in metastasis, suggesting that PACC can enhance metastatic potential.
- Evidence from previous studies shows that the presence of PACC in patient tumors correlates with a higher risk of future metastasis, prompting the use of innovative methods to analyze circulating and disseminated tumor cells from animal models.
- The findings reveal that a significant majority of these tumor cells were in the PACC state, and specific traits associated with PACC contribute to its ability to spread and colonize new sites, raising concerns about the effectiveness of certain cancer treatments that may inadvertently promote metastasis.
Therapeutic resistance in cancer significantly contributes to mortality, with many patients eventually experiencing recurrence after initial treatment responses. Recent studies have identified therapy-resistant large polyploid cancer cells in patient tissues, particularly in late-stage prostate cancer, linking them to advanced disease and relapse. Here, we analyzed bone marrow aspirates from 44 advanced prostate cancer patients and found the presence of CTC-IGC was significantly associated with poorer progression-free survival.
View Article and Find Full Text PDFWithin Xenarthra (Eocene-Recent), Folivora developed (late Eocene-Recent) a remarkable diversity with respect to ecology and taxonomy over its evolutionary history. Knowledge of the diversity achieved by members of this clade in high-altitude areas of South America (i.e.
View Article and Find Full Text PDFBody composition in recurrent prostate cancer and the role of steroidogenic genotype.
Endocr Relat Cancer
December 2024
Hormone therapy (HT) to treat prostate cancer is reported to cause adverse changes in body composition. Clinically, interpatient body composition changes are heterogeneous, but the biological and clinical determinants of body composition toxicity are unknown. Herein, we test the hypothesis that inherited polymorphisms in steroidogenic genes are associated with differential changes in body composition after HT.
View Article and Find Full Text PDFBackground And Objective: Belzutifan, a hypoxia-inducible factor 2 alpha inhibitor, was approved initially for patients with von Hippel-Lindau disease and more recently for sporadic, metastatic clear cell renal cell carcinoma (ccRCC) based on the results of LITESPARK-005. There is a paucity of data regarding real-world experience with belzutifan in patients with sporadic, metastatic ccRCC. This study aims to describe clinical outcomes with belzutifan in patients with sporadic, metastatic ccRCC.
View Article and Find Full Text PDF